- Tumors1000+
- Cancer857
- Pathology701
- Pathologic Processes694
- Immune System Diseases532
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer857
- Pathology701
- Pathologic Processes694
- Immune System Diseases532
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PD-L1 negative
- ER negative
- PR negative
- EGFR negative
- EGFR positive
- ALK negative
- BRAF positive
- KRAS positive
- BRCA1 positive
- BRCA2 positive
- BRAF negative
- CD20 positive
- p16 positive
- CD19 positive
- HLA-A positive
- ROS1 negative
- ALK positive
- HLA positive
- MYC positive
- p16 negative
- HR positive
- MET positive
- PIK3CA positive
- TP53 positive
- IDH positive
- BCL2 positive
- CCND1 positive
- CD5 positive
- HBsAg positive
- HPV negative
- L858R positive
- MET negative
- RB1 positive
- RET positive
- ex19del positive
- BCL6 positive
- HLA negative
- PALB2 positive
- RB1 negative
- ROS1 positive
- t(11;14) positive
- Anti-dsDNA positive
- BCR-ABL1 positive
- BRCA positive
- BRCA1 negative
- HLA-A negative
- IDH negative
- NRAS positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- RET negative
- T790M positive
- TTR positive
- ctDNA positive
- ANA positive
- BRCA2 negative
- CD30 positive
- CLDN18.2 positive
- EBV positive
- FGFR2 positive
- FLT3 negative
- HPV positive
- MMR positive
- NTRK negative
- TERT positive
- TP53 negative
- TROP2 negative
- TROP2 positive
- dMMR positive
- p53 positive
- 17p deletion positive
- ABCA4 positive
- APP positive
- ATM positive
- C5 positive
- CD123 positive
- CD23 positive
- CD4 positive
- CFTR positive
- COL7A1 positive
- FLT3 positive
- FMR1 positive
- HBB positive
- HBsAg negative
- HRD positive
- KIT positive
- KRAS negative
- MDM2 positive
- MSI-H positive
- MYC negative
- NF1 positive
- NF2 positive
- NRAS negative
- PSEN1 positive
- PSEN2 positive
- PTEN positive
- RAS negative
- RF positive
- SPINK5 positive
- t(9;22) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- ALPL positive
- ATRX negative
- ATRX positive
- Anti-Smith positive
- Aβ1-42 positive
- BRCA negative
- CCND1 negative
- CD19 negative
- CD20 negative
- CD8 positive
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- CTC1 positive
- DICER1 positive
- DKC1 positive
- DMD positive
- ER/PR positive
- EZH2 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GLA positive
- HRAS positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- L861Q positive
- MGMT negative
- MMR negative
- MSI-H negative
- MSS positive
- NHP2 positive
- NOP10 positive
- NTRK positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PTEN negative
- PiZZ positive
- RAS positive
- S768I positive
- SMARCB1 negative
- SMARCB1 positive
- SMN1 positive
- STK11 positive
- T315I positive
- TERC positive
- TMB positive
- TTR negative
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- dMMR negative
- del(17p) negative
- hepatitis B DNA negative
- other sickle cell syndrome variants positive
- t(1;19) positive
- t(4;11) positive
- (null)(null) positive
- 11q aberration positive
- 11q del negative
- 11q23 abnormalities positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q deletion negative
- 19q deletion positive
- 19q negative
- 19q positive
- 1p deletion negative
- 1p deletion positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q codeletion negative
- 1p/19q loss positive
- 1p/19q positive
- 1p19q co-deletion negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- >= 2 Bone Metastases (Untreated Lesion)
- ANC >= 1,500/mcL
- AST/ALT =< 3 x ULN
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Allogeneic Hematopoietic Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplant
- Anthracycline
- Anti-HER2 Therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3718 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Acute Lymphoblastic Leukemia trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new chemotherapy treatment for leukemia that includes an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 34 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Approved for 20 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying giving chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares ipilimumab to interferon alfa-2b to see which is more effective in treating patients with high-risk stage III-IV melanoma.
Efficacy & Safety Awards
All Individual Drugs Already Approved
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing 4 different hormone therapies with or without chemotherapy to see which is most effective in treating patients with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 34 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares lenalidomide to observation in treating patients with asymptomatic high-risk multiple myeloma. It is not yet known whether lenalidomide is more effective than observation alone.
Efficacy & Safety Awards
All Individual Drugs Already Approved
Approved for 20 Other Conditions
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying gemcitabine hydrochloride given with or without erlotinib hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil, to see how well it works in treating patients with pancreatic cancer that has been removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different sets of cancer drugs to see which works better for patients with advanced neuroendocrine carcinoma that has spread or cannot be removed by surgery. The drugs aim to stop cancer from growing and spreading by attacking the cancer cells in different ways. One of the drugs being tested is used for treating advanced neuroendocrine tumors.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Acute Lymphoblastic Leukemia trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the side effects and efficacy of blinatumomab and combination chemotherapy or dasatinib and prednisone in treating older patients with acute lymphoblastic leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 1 & 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the side effects and best dose of two drugs, pomalidomide and ixazomib, when given together with dexamethasone, to treat patients with multiple myeloma that has come back.
Efficacy & Safety Awards
No Placebo-Only Group
1
2
3
…50